We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

FDA Expands Skytrofa Approval to Adults with Growth Hormone Deficiency: Clinical and Practice Implications

MedXY Editorial Team•Sep 30, 2025•Clinical Updates
FDA approvalgrowth hormone deficiencySkytrofa

Highlight

– The FDA has approved lonapegsomatropin-tcgd (Skytrofa) for adults with growth hormone deficiency (GHD), expanding its original pediatric indication.
– In the phase 3 foresiGHt trial, once-weekly lonapegsomatropin was superior to placebo and comparable to daily somatropin in improving body composition, with similar safety outcomes.
– Skytrofa’s weekly regimen addresses a significant unmet need for treatment convenience and may enhance adherence among adult GHD patients.
– The approval is expected to influence clinical practice and prompt updates to adult GHD management guidelines.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Metabolic and Muscular Impacts of Switching from Daily Somatropin to Weekly Somapacitan in Adult Growth Hormone Deficiency: Real-World EvidenceSwitching from daily somatropin to once-weekly somapacitan in adults with growth hormone deficiency maintains lean mass, improves functional outcomes, but may increase adiposity indices, highlighting a trade-off in metabolic effects duringAug 18, 2026Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major DepressionThis article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tranAug 11, 2026Addressing Critical Barriers to Corneal Cross-Linking in US Keratoconus Care: Navigating the Transition from Photrexa® to Epioxa™This article examines disparities in access to corneal cross-linking (CXL) for keratoconus patients in the US, highlighting challenges posed by high costs, insurance limitations, and the transition from Photrexa® to Epioxa™.Aug 2, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
In Transition-Age Childhood-Onset GH Deficiency, Glucagon Test Results Reflect Pituitary Damage More Than Body Mass IndexIn 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.May 31, 2026
FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for ChildrenThe FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.Nov 6, 2025
Understanding the FDA’s Rejection of SYD-101: Navigating the Challenges in Pediatric Myopia TreatmentThe FDA has rejected Sydnexis’s low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in Nov 4, 2025